The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Taysha Gene Therapies Inc (NASDAQ: TSHA) was $4.88 for the day, up 53.46% from the previous closing price of $3.18. In other words, the price has increased by $53.46 from its previous closing price. On the day, 123.03 million shares were traded. TSHA stock price reached its highest trading level at $4.92 during the session, while it also had its lowest trading level at $3.98.
Ratios:
Our analysis of TSHA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, BofA Securities on July 11, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On June 27, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $5.
On April 09, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $9.Piper Sandler initiated its Overweight rating on April 09, 2024, with a $9 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 22 ’25 when Rumana Haque-Ahmed bought 10,770 shares for $2.83 per share.
Nagendran Sukumar sold 200,000 shares of TSHA for $646,000 on Sep 10 ’25. The President and Head of R&D now owns 1,006,439 shares after completing the transaction at $3.23 per share. On Sep 10 ’25, another insider, Nagendran Sukumar, who serves as the Officer of the company, bought 200,000 shares for $3.26 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 1331239040 and an Enterprise Value of 1078242048. For the stock, the TTM Price-to-Sale (P/S) ratio is 164.35 while its Price-to-Book (P/B) ratio in mrq is 5.35. Its current Enterprise Value per Revenue stands at 133.149 whereas that against EBITDA is -12.252.
Stock Price History:
The Beta on a monthly basis for TSHA is 0.95, which has changed by 1.4278607 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $3.40, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 63.92%, while the 200-Day Moving Average is calculated to be 118.50%.
Shares Statistics:
TSHA traded an average of 3.38M shares per day over the past three months and 17343630 shares per day over the past ten days. A total of 272.73M shares are outstanding, with a floating share count of 222.28M. Insiders hold about 18.52% of the company’s shares, while institutions hold 87.01% stake in the company. Shares short for TSHA as of 1757894400 were 43357026 with a Short Ratio of 12.82, compared to 1755216000 on 36406713. Therefore, it implies a Short% of Shares Outstanding of 43357026 and a Short% of Float of 17.76.
Earnings Estimates
Taysha Gene Therapies Inc (TSHA) is currently under the scrutiny of 4.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.25 and -$0.39 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.44, with 4.0 analysts recommending between -$0.26 and -$0.55.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $4.3M, resulting in an average revenue estimate of $7.52M. In the same quarter a year ago, actual revenue was $8.33M
